Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer

Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer

US Patent 10238630 · Granted Mar 26, 2019

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Polypeptide and application thereof in bone repair2024
Chlorotoxin agents and uses thereof2023
High-quality seawater Spirulina strain obtained by space-breeding and use thereo2021
Markers for breast cancer2019
Method for the protection of trees2018
Markers for breast cancer2017
Use of eribulin and lenvatinib as combination therapy for treatment of cancer2017
Markers for breast cancer2015
Markers for breast cancer2015
Method for the protection of trees2014
Multikinase inhibitors for use in the treatment of cancer2013
Method and system for optimising land levelling designs2011